Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063
Invivyd (NASDAQ:IVVD) provided updates on its REVOLUTION program for COVID-19 monoclonal antibody candidate VYD2311 and announced the discovery and early development work for a measles monoclonal antibody candidate, VMS-063, during a conference call led by board chairman Marc Elia alongside Chief Sc...